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I

n the pre-antibiotic era and early antibiotic era,
streptococci were the prevalent causative microorganisms for infective endocarditis (IE) while
rheumatic heart disease was the most common
predisposing cause. At that time, antibiotic prophylaxis before dental procedure was recommended [1].
Turning into the 21st century, a changing face of
IE was observed. While the overall incidence rate
remained relatively stable, there were changes in
epidemiology, predisposing aetiology and microbiology. Degenerative valve diseases, prosthetic
valves, intravenous drug use and implantation of
cardiovascular implantable electronic devices
(CIED) emerged as more important predisposing
conditions, while the prevalence of rheumatic heart
disease decreased. This was a pattern that was
evident in developed countries, where improvement
in health care was not shown to lower the incidence
of IE. Instead, healthcare associated infective endocarditis (HCAIE) has gained signiﬁcance, due to
increased use of CIED and more widespread use of
various other invasive diagnostic and therapeutic
procedures which predisposed to bacteremia. Going
along with this change in epidemiology was the
growing importance of staphylococci as culprit microorganisms [2,3]. Between 2007 and 2009, revised
international guidelines restricted antibiotic prophylaxis only for patients at highest risk [4,5].
Various observational studies have looked into

whether this change in practice led to increase in
incidence of IE, with inconsistent results [2,3].
In various parts of the world with different economies and different medical resources, variations in
change in epidemiology are expected [2]. The local
situation is less clear as data are limited. An early
local study of community acquired IE in the period
between 1995 and 2005 indicated stable incidence in
the 10-year period, with intravenous drug addiction
followed by chronic rheumatic heart disease being
the most common predisposing causes [6]. In this
issue of the Journal, Yiu reported a single-center
study on IE cases from 2002 to 2016 [7]. It likewise
showed a stable incidence rate in the study period.
The in-hospital mortality was high at 29.1% which
was comparable to other reports [2,3]. Notably,
HCAIE accounted for a signiﬁcant proportion of 32%
and the proportion of HCAIE showed increasing
trend over years. Importantly, HCAIE was associated with a higher mortality of 52.4% as compared to
community acquired IE (mortality 18.0%), though
the difference became insigniﬁcant after adjustment
for Charlson comorbidity index. Regarding microbiology, Staphylococcus aureus was the most prevalent isolated microorganism, which carried a worse
outcome as compared to streptococcal IE. Remarkably, methicillin resistance was increasingly
observed over the study period. The ﬁndings of this
study were similarly seen in another local study just
published [8]. These studies together added to the
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literature and provided insight that the epidemiology of IE in Hong Kong changed in a similar
pattern reported in other developed countries. More
importantly, these ﬁndings should heighten the
awareness of growing signiﬁcance of HCAIE and call
for meticulous efforts to minimize bacteremia during
intravascular procedures, which are key preventive
measures for IE, and are crucial for tackling this old
problem with a changing face.
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